Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

458 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of > or = 300/mm3: CPCRA 059.
Abrams DI, Bebchuk JD, Denning ET, Davey RT, Fox L, Lane HC, Sampson J, Verheggen R, Zeh D, Markowitz NP; Terry Beirn Community Programs for Clinical Research on AIDS. Abrams DI, et al. Among authors: lane hc. J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):221-31. doi: 10.1097/00126334-200203010-00002. J Acquir Immune Defic Syndr. 2002. PMID: 11873071 Clinical Trial.
High prevalence of osteonecrosis of the femoral head in HIV-infected adults.
Miller KD, Masur H, Jones EC, Joe GO, Rick ME, Kelly GG, Mican JM, Liu S, Gerber LH, Blackwelder WC, Falloon J, Davey RT, Polis MA, Walker RE, Lane HC, Kovacs JA. Miller KD, et al. Among authors: lane hc. Ann Intern Med. 2002 Jul 2;137(1):17-25. doi: 10.7326/0003-4819-137-1-200207020-00008. Ann Intern Med. 2002. PMID: 12093241 Free article.
Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection.
Natarajan V, Lempicki RA, Sereti I, Badralmaa Y, Adelsberger JW, Metcalf JA, Prieto DA, Stevens R, Baseler MW, Kovacs JA, Lane HC. Natarajan V, et al. Among authors: lane hc. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10712-7. doi: 10.1073/pnas.162352399. Epub 2002 Jul 29. Proc Natl Acad Sci U S A. 2002. PMID: 12149467 Free PMC article. Clinical Trial.
A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 CD4+ T cells.
de Boer AW, Markowitz N, Lane HC, Saravolatz LD, Koletar SL, Donabedian H, Yoshizawa C, Duliege AM, Fyfe G, Mitsuyasu RT. de Boer AW, et al. Among authors: lane hc. Clin Immunol. 2003 Mar;106(3):188-96. doi: 10.1016/s1521-6616(02)00038-4. Clin Immunol. 2003. PMID: 12706405 Clinical Trial.
Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover.
Anthony KB, Yoder C, Metcalf JA, DerSimonian R, Orenstein JM, Stevens RA, Falloon J, Polis MA, Lane HC, Sereti I. Anthony KB, et al. Among authors: lane hc. J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):125-33. doi: 10.1097/00126334-200306010-00002. J Acquir Immune Defic Syndr. 2003. PMID: 12794543
A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.
Tavel JA, Sereti I, Walker RE, Hahn B, Kovacs JA, Jagannatha S, Davey RT Jr, Falloon J, Polis MA, Masur H, Metcalf JA, Stevens R, Rupert A, Baseler M, Lane HC. Tavel JA, et al. Among authors: lane hc. J Infect Dis. 2003 Aug 15;188(4):531-6. doi: 10.1086/377285. Epub 2003 Jul 31. J Infect Dis. 2003. PMID: 12898439 Clinical Trial.
458 results